Strategic Investment in mPharma Ghana
Growth Investment Partners (GIP) Ghana Ltd, an investment platform established by British International Investment (BII), has made a significant strategic investment in mPharma Ghana Ltd. This move aims to enhance the healthcare landscape in Africa by supporting a patient-centred and technology-driven company that is focused on improving access to affordable medicines.
The investment from GIP will allow mPharma to optimize its inventory management within the Mutti pharmacy network across Ghana and Francophone West Africa (FWA). Additionally, it will support the expansion of the QualityRx franchise model into new markets in the West African region. This initiative is designed to empower local pharmacy owners and expand access to community-based healthcare in Togo and Benin.
Mr Jacob Kholi, Chief Executive and Investment Officer of GIP Ghana, emphasized the importance of this partnership. He stated, “Our focus remains on supporting high-impact businesses that improve essential services for everyday people. Strengthening mPharma’s footprint in Francophone West Africa will help more communities access affordable medicines while reinforcing the resilience of regional healthcare systems.”
A Vision for Affordable Healthcare
Founded in 2013, mPharma has emerged as one of Africa’s most innovative healthcare providers. The company addresses the persistent challenge of limited access to affordable medicines by leveraging technology and a patient-centric approach.
Through its Mutti pharmacy network and complementary services like Mutti Doctor—a virtual consultation and community screening service—mPharma ensures timely access to licensed doctors. This reduces patient wait times from hours to minutes and promotes early detection and management of chronic conditions.
The company’s franchise model offers pharmacy owners a multi-year partnership that has enabled mPharma to build a broad pharmacy network. This network brings affordable care closer to communities, converting independent community pharmacies into trusted primary healthcare access points under the Mutti brand.
Expanding Reach and Impact
Mr Kwesi Arhin, Chief Executive Officer of mPharma, highlighted the significance of this investment. He said, “Access to affordable medicines remains one of the most critical healthcare challenges across the region. With GIP’s support, we can continue to strengthen our partnerships with pharmacies and healthcare providers to enhance patient care and ensure equitable access to quality medicines across Ghana, Francophone West Africa, and the wider Sub-Saharan region.”
Mr Kwabena Asante-Poku, BII Country Director, Ghana, expressed pride in deepening their support for mPharma through GIP’s investment. He noted, “We are proud to deepen our support for mPharma through GIP’s investment. BII has been an investor in mPharma for several years, and we have seen firsthand the company’s impact in improving access to affordable medicines and healthcare across Africa. This new partnership will help accelerate mPharma’s expansion in Francophone West Africa, strengthening health systems and delivering essential services to more communities.”
Measurable Success
mPharma’s impact is already evident. Its Mutti membership programme has grown from fewer than 10,000 members in 2019 to more than 400,000 at the end of 2024 across Africa. Over 70 per cent of patients report lower drug prices at Mutti pharmacies, while more than 75 per cent of members report no stockouts of essential medicines.
This growth underscores the effectiveness of mPharma’s approach and the positive changes it has brought to communities across the continent. With continued support and expansion, the company is poised to make an even greater impact on healthcare accessibility in Africa.